



XIV

CONGRESSO
NAZIONALE
IG-IBD

A BRIDGE TO THE FUTURE

30 NOVEMBRE - 2 DICEMBRE 2023
SALA CONCORDIA

FACULTY

Maria T. Abreu, *Miami (USA)*

Maria Paola Anolli, *Milano*

Sandro Ardizzone, *Milano*

Alessandro Armuzzi, *Rozzano (MI)*

Brigida Barberio, *Padova*

Cristina Bezzio, *Rozzano (MI)*

Giorgia Bodini, *Genova*

Alessandra Brancaleoni, *Rimini*

Andrea Buda, *Feltre (BL)*

Emma Calabrese, *Roma*

Gabriella Canavese, *Torino*

Flavio A. Caprioli, *Milano*

Fabiana Castiglione, *Napoli*

Ferdinando D'Amico, *Milano*

Silvio Danese, *Milano*

Marco Daperno, *Torino*

Gabriele Dragoni, *Firenze*

Nikolas K. Dussias, *Bologna*

Emilio Paolo Emma, *Firenze*

Massimo C. Fantini, *Monsestato (CA)*

Ennio G. Favalli, *Milano*

Stefano Festa, *Roma*

Gionata Fiorino, *Roma*

Marianna Franco, *Feltre (BL)*

Roberto Gerli, *Perugia*

Paolo Gionchetti, *Bologna*

David Laharie, *Bordeaux (FR)*

Loris R. Lopetuso, *Roma*

Fabio S. Macaluso, *Palermo*

Letizia Masi, *Roma*

Laura Melotti, *Bologna*

Giammarco Mocci, *Cagliari*

Giovanni Monteleone, *Roma*

Alessandra Narcisi, *Rozzano (MI)*

Daniele Noviello, *Milano*

Sara Onali, *Monsestato (CA)*

Ambrogio Orlando, *Palermo*

Claudio Papi, *Roma*

Andrea Pasta, *Genova*

Federica Perillo, *Milano*

Valentina Petito, *Roma*

Mariabatrice Principi, *Bari*

Giuseppe Privitera, *Milano*

Daniela Pugliese, *Roma*

Timo Rath, *Erlangen (DE)*

Davide G. Ribaldone, *Torino*

Antonio Rispo, *Napoli*

Fernando Rizzello, *Bologna*

Simone Saibeni, *Rho (MI)*

Edoardo V. Savarino, *Padova*

Bo Shen, *New York (USA)*

Gian Eugenio Tontini, *Milano*

Federica Ungaro, *Milano*

Angela Variola, *Negrar (VR)*

Maurizio Vecchi, *Milano*

Stefania Vetrano, *Pieve Emanuele (MI)*

Anna Viola, *Messina*



PROGRAMMA

30 NOVEMBRE 2023

14.00–14.30 **Opening remarks**
F.A. Caprioli, IG-IBD
V. Ferracuti, AMICI ETS

LECTURE

Chair: F. Castiglione

14.30–15.00 **IG-IBD and SIR consensus on SpA-IBD**
F.S. Macaluso, R. Gerli

SESSION I ORAL COMMUNICATIONS

Chairs: G. Bodini, F. Rizzello

15.00–15.10 **Perception of disease impact and activity in Italian IBD patients vs Physicians: an IBD-PODCAST study subanalysis**
E.V. Savarino

15.10–15.20 **Prevalence of gastrointestinal infections in ulcerative colitis patients assessed with QIAstat-Dx® Gastrointestinal Panel 2**
M.P. Anolli

15.20–15.30 **The real-life use of the Crohn's disease exclusion diet (CDED) in adults with mild-to-moderate Crohn's disease activity: an interim analysis of an open-label randomized controlled trial**
A. Pasta

15.30–15.40 **Pre-operative exposure to tofacitinib is as safe as biologics in patients with ulcerative colitis undergoing colectomy: a multicentre observational study**
G. Dragoni

PROGRAMMA

30 NOVEMBRE 2023



- 15.40–15.50 **Immunogenicity and safety of adjuvanted recombinant zoster vaccine in patients with Inflammatory Bowel Disease on different immunosuppressive therapies**
M. Franco
- 15.50–16.00 **Real-world efficacy and safety of Ustekinumab in managing ulcerative colitis**
G. Mocchi
- 16.00–16.30 *Coffee break*

SESSION II Not only a gastrointestinal disease

Chairs: C. Bezzio, M. Vecchi

- 17.45–18.00 **Concomitant Immune-Mediated Inflammatory Diseases**
D.G. Ribaldone
- 18.00–18.15 **Paradoxical effects of therapies**
D. Pugliese
- 18.15–19.00 **Round Table**
The need and the modalities of a multidisciplinary approach
A. Brancaleoni, E.G. Favalli, A. Narcisi
- 19.00–19.15 **Discussion**



PROGRAMMA

1 DICEMBRE 2023

LECTURE

Chair: *M. Principi*

08.30–09.00 **Treatment sequencing: practical guide**
A. Orlando

SESSION III ORAL COMMUNICATIONS

Chairs: *E. Calabrese, E.V. Savarino*

- 09.00–09.10 **Switching from intravenous to subcutaneous infliximab and vedolizumab in IBD in clinical remission is associated with a lower rate of drug discontinuation, drug optimization, and reverse-switch: an international multicenter study**
F. D'Amico
- 09.10–09.20 **Long term follow-up of patients with ulcerative colitis after suspension of infliximab for stable deep remission**
N.K. Dussias
- 09.20–09.30 **Oral mannitol versus PEG-ASC for bowel preparation: a post-hoc analysis on IBD patients from satisfaction study**
G.E. Tontini
- 09.30–09.40 **Monitoring Crohn's disease patients in clinical remission: the role of intestinal ultrasound**
L. Melotti
- 09.40–09.50 **Preliminary report on short-term post-operative outcomes of robotic versus laparoscopic approach for restorative procto-colectomy with ileal-pouch-anal anastomosis in ulcerative colitis: a comparative study**
E.P. Emma

PROGRAMMA

1 DICEMBRE 2023

09.50–10.00 **The histology driven differential diagnosis in bowel inflammatory conditions: it's not all that obvious. Evidence from a survey based on digital slides**
G. Canavese

10.00–10.30 *Coffee break*

SESSION IV IBD and environment: an update

Chairs: S. Ardizzone, G. Monteleone

11.15–11.35 **Old and new risk factors in the pathogenesis**
M.C. Fantini

11.35–11.55 **The role of diet in preventing and modifying disease course**
Live Streaming
M.T. Abreu

11.55–12.15 **Microbiota**
L.R. Lopetuso

12.15–12.45 **Discussion**

12.45–13.45 *Lunch*

LECTURE

Chairs: C. Papi, S. Saibeni

15.00–15.20 **Pragmatic trials: when, how and why**
G. Fiorino

15.20–15.30 Discussion



PROGRAMMA

1 DICEMBRE 2023

SESSION V ORAL COMMUNICATIONS

Chairs: F. Ungaro, S. Vetrano

- 15.30–15.40 **Microbial-derived metabolites promote NKT22 responses in colitis associated colorectal cancer patients**
F. Perillo
- 15.40–15.50 **A specific microbiota signature is associated to immunotherapy-related colitis as assessed by a machine learning approach. A comparative study with Inflammatory Bowel Diseases and healthy controls**
B. Barberio
- 15.50–16.00 **The solute transporter OCTN1/SLC22A4 affects disease severity and response to infliximab in experimental colitis: role of gut microbiota and immune modulation**
L. Masi
- 16.00–16.10 **Immune and non immune changes following FMT in experimental colitis: emerging pathways of FMT-derived mucosal healing**
V. Petito
- 16.10–16.20 **Differential effects of P40 and P19 inhibition in modulating tissue-resident TH17 cell subsets in Crohn's disease patients: an exploratory in vivo study**
D. Noviello

PROGRAMMA

1 DICEMBRE 2023

16.20–16.30 **Human extrachromosomal circular DNA is an emerging biomarker in Inflammatory Bowel Disease**
V. Petito

16.30–17.00 *Coffee break*

SESSION VI **Difficult-to-manage patients**

Chairs: P. Gionchetti, A. Variola

17.00–17.20 **Pouchitis**
Live Streaming *B. Shen*

17.20–17.40 **When colitis is not IBD**
S. Festa

17.40–18.00 **Previous or current neoplasm**
S. Onali

18.00–18.20 Discussion

18.30–19.30 ASSEMBLEA ORDINARIA DEI SOCI IG-IBD



PROGRAMMA

2 DICEMBRE 2023

LECTURE

Chair: *G.E. Tontini*

08.30–09.00 **The future of endoscopy in IBD**
T. Rath

SESSION VII ORAL COMMUNICATIONS

Chairs: *A. Buda, M. Daperno*

09.00–09.10 **Efficacy and safety outcomes up to ~4 years of treatment with filgotinib 200 mg among patients with ulcerative colitis: results from the selection LTE study**
S. Ardizzone

09.10–09.20 **Achievement of stringent efficacy endpoints in patients with moderately to severely active Crohn's disease treated with upadacitinib**
S. Danese

09.20–09.30 **Switching from vedolizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: the SVEDO study, an IG-IBD study**
D.G. Ribaldone

09.30–09.40 **Risankizumab induction therapy in patients with moderately to severely active ulcerative colitis: efficacy and safety in the randomized PHASE 3 inspire study**
A. Armuzzi

PROGRAMMA

2 DICEMBRE 2023

- 09.40–09.50 **Effectiveness and safety outcomes beyond five years of IBD patients treated with vedolizumab. The LONG-LIVE IG-IBD study**
G. Privitera
- 09.50–10.00 **Improvement in bowel urgency is associated with stool frequency and rectal bleeding remission at 12 and 52 weeks in patients with moderately-to-severely active ulcerative colitis**
M. Daperno
- 10.00–10.30 *Coffee break*

SESSION VIII Evolving strategies in IBD

Chairs: S. Danese, A. Viola

- 11.15–11.35 **Treat-to-Target: between myth and reality**
A. Rispo
- 11.35–11.55 **Therapy: Mono vs Combo, Single vs Dual**
A. Armuzzi
- 11.55–12.15 **Post-surgical recurrence of Crohn's disease**
G. Dragoni
- 12.15–12.30 **Discussion**

LECTURE

- 12.30–13.00 **Emerging and promising future therapies for IBD**
D. Laharie
- 13.00–13.10 **Conclusions**



INFORMAZIONI GENERALI

ACCREDITAMENTO ECM

Questo evento è accreditato dal Provider Nazionale Health Meetings Group Srl (6083-397477 Ed.1) per le figure professionali del Dietista, Infermiere e Medico Chirurgo nelle discipline di Gastroenterologia, Medicina Interna, Chirurgia Generale, Anatomia Patologica, Pediatria, Pediatria (Pediatri di Libera Scelta), Scienza dell'alimentazione e dietetica.

L'evento prevede l'assegnazione di n. **3,6 CREDITI FORMATIVI**.

Si ricorda che l'acquisizione dei Crediti Formativi ECM è subordinata al rispetto di quanto segue:

- 90% di PRESENZA durante i lavori scientifici (rilevazione elettronica delle presenze)
- CONSEGNA del modulo di valutazione dell'evento e del modulo ANAGRAFICA
- APPARTENENZA alle discipline per le quali è stato richiesto l'accREDITAMENTO

Non è prevista verifica di apprendimento.

QUESTO EVENTO È REALIZZATO CON IL CONTRIBUTO
NON CONDIZIONANTE DI

abbvie

AGpharma
Dicofarm group

ALFASIGMA 

biosphæra[®]
PHARMA

 **CADIGROUP[®]**
FARMACEUTICI

 HEALTHCARE
CELLTRION

 **Chiesi**


Difass International S.p.a.

Lilly

FERRING
PHARMACEUTICALS

Galápagos
Pioneering for patients

GIULIANI

janssen  Immunology
PHARMACEUTICAL COMPANIES OF *Johnson & Johnson*

KEDRION
BIOPHARMA

 **MSD**

 **Nestlé**
HealthScience

 **Pfizer**

SANDOZ A Novartis
Division

 **Takeda**

